Abstract: In vitro cell-based assays have been fundamental in modern drug discovery and have led to the identification of novel therapeutics. We have developed complex mixed central nervous system (CNS) cultures, which recapitulate the normal process of myelination over time and allow the study of several parameters associated with CNS damage, both during development and after injury or disease. In particular, they have been used as a reliable screen to identify drug candidates that may promote (re)myelination and/or neurite outgrowth. Previously, using these cultures, we demonstrated that a panel of low sulphated heparin mimetics, with structures similar to heparan sulphates (HSs), can reduce astrogliosis, and promote myelination and neurite outgrowth. HSs reside in either the extracellular matrix or on the surface of cells and are thought to modulate cell signaling by both sequestering ligands, and acting as co-factors in the formation of ligand-receptor complexes. In this study, we have used these cultures as a screen to address the repair potential of numerous other commercially available sulphated glycomolecules, namely heparosans, ulvans, and fucoidans. These compounds are all known to have certain characteristics that mimic cellular glycosaminoglycans, similar to heparin mimetics. We show that the N-sulphated heparosans promoted myelination. However, O-sulphated heparosans did not affect myelination but promoted neurite outgrowth, indicating the importance of structure in HS function. Moreover, neither highly sulphated ulvans nor fucoidans had any effect on remyelination but CX-01, a low sulphated porcine intestinal heparin, promoted remyelination in vitro. These data illustrate the use of myelinating cultures as a screen and demonstrate the potential of heparin mimetics as CNS therapeutics.
Introduction
The repair of the central nervous system (CNS) is a complex process, which requires a multifactorial approach. Identifying molecules that promote CNS repair is an important aspect of developing therapies for regenerative medicine. We have devised a mixed neural cell culture that can be used to study developmental myelination, neurite outgrowth, and re/myelination after injury. The cultures are generated from dissociated embryonic rat spinal cords and develop over time to form many myelinated internodes separated by nodes of Ranvier [1] . They have allowed us to examine factors that regulate the process of myelination over time and we have, therefore, termed them myelinating cultures-development (MC-Dev). These cultures have been used to study the interaction between oligodendrocytes and axons during the process of myelination [2] and lead to the identification of the Step 2) and allowed to develop for at least 24 days (Step 3). Therapeutics can be introduced from when the process of myelination begins (day [12] [13] [14] [15] [16] to determine their effect on de novo myelination. (b) The cultures can be used to mimic CNS injury (MC-Inj) by cutting with an 11 mm single edge razor blade pressed gently across the center of the coverslip on day 24 (Step 4). The day after injury, cultures can be treated with therapeutics and the extent of neurite outgrowth (SMI31 stains axons in red, DAPI stains nuclei blue) or myelination (PLP stains myelin in green) adjacent to the injury site quantified (Step 5). Dotted white line demarcates injury site. (c) To study remyelination, the cultures are demyelinated by overnight incubation with the Z2 antibody that recognizes myelin oligodendrocyte glycoprotein (MOG) and rabbit complement at 37 °C (Step 4). The day after demyelination the cultures can be treated with Figure 1 . Schematic of in vitro myelinating cultures MC-Dev, MC-Inj, and MC-Demy. (a) MC-Dev are set up using astrocytes derived from neurospheres (Step 1, GFAP stains astrocytes in green) and mixed spinal cord cells derived from embryos at day 15 ( Step 2) and allowed to develop for at least 24 days (Step 3). Therapeutics can be introduced from when the process of myelination begins (day [12] [13] [14] [15] [16] to determine their effect on de novo myelination. (b) The cultures can be used to mimic CNS injury (MC-Inj) by cutting with an 11 mm single edge razor blade pressed gently across the center of the coverslip on day 24 (Step 4). The day after injury, cultures can be treated with therapeutics and the extent of neurite outgrowth (SMI31 stains axons in red, DAPI stains nuclei blue) or myelination (PLP stains myelin in green) adjacent to the injury site quantified (Step 5). Dotted white line demarcates injury site. (c) To study remyelination, the cultures are demyelinated by overnight incubation with the Z2 antibody that recognizes myelin oligodendrocyte glycoprotein (MOG) and rabbit complement at 37 • C (Step 4). The day after demyelination the cultures can be treated with therapeutics and after 5 days the levels of remyelination quantified compared to non-treated control cultures (Step 5). Scale bars represents 100 µm. The final compound in our library of glycomolecules was the low anticoagulant 2-O, 3-O desulphated heparin (ODSH, CX-01), which is a porcine intestinal heparin derivative that retains many heparin anti-inflammatory properties. It is well-characterised, commercially available, and is currently involved in a clinical trial for acute myeloid leukemia [32] . It was also used as an early therapeutic intervention after traumatic brain injury and showed beneficial functional outcomes [33] . We were, therefore, interested to determine if such beneficial effects could be observed in our in vitro CNS injury models.
Using our three complex neural cultures (MC-Inj, MC-Dev, and MC-Demy), we were able to screen this library of sulphated polysaccharides to establish any effect on re/myelination and neurite outgrowth. We have identified a number of interesting compounds, demonstrating the suitability of these complex cultures for screening potential therapeutics.
Materials and Methods

Library of Glycomolecules
Heparosans were gifted by Glycores 2000 Srl (Milan, Italy), and ulvans were produced and modified by Glycomar Ltd. (Oban, UK). The fucoidans were gifted for research use by Marinova Pty Ltd. (fucoidans 1, 3 and 5, Cambridge, Australia) and FMC Biopolymer (fucoidans 2 and 4, Vormedal, Norway). Glycomar Ltd. (UK) carried out desulphation and depolymerisation of fucoidans (fucoidans 1, 2 and 3). Cantex Pharmaceuticals (Weston, FL, USA) gifted the CX-01 compound.
Astrocytes Derived from Neurospheres
Neurospheres (NS) were generated from the striata of 1-day-old Sprague Dawley (SD) rat pups using a method modified by [34] and differentiated into astrocytes as described in [1, 3] . Neurospheres were triturated and transferred to 13 mm poly-L-lysine (PLL; 13 µg/mL, Sigma, Gillingham, UK) coated coverslips (Corning, Deeside, UK) and incubated for a further 5-7 days in vitro (DIV) at 37 • C in an atmosphere of 7% CO 2 until a confluent monolayer formed. Neurosphere-derived astrocytes were maintained in Dulbecco's modified Eagle's medium (DMEM-1 g/mL glucose, Life Technologies, Paisley, UK) with 10% fetal bovine serum (Sigma, UK) and 2 mM L-glutamine (Sigma, Gillingham, UK).
Myelinating Spinal Cord Cultures (MC-Dev)
Generation of rat myelinating cultures was based on previously described methods [1] . The spinal cord of E15.5 Sprague Dawley (SD) embryos were enzymatically dissociated and the cell suspension was plated at 150,000 cells per coverslip on top of the neurosphere derived astrocytes in a plating medium (PM) that contained 50% DMEM-1 g/mL glucose, 25% horse serum (Invitrogen), 25% HBSS (with Ca 2+ and Mg 2+ , Life Technologies, UK), and 2 mM L-glutamine. Cells were left to adhere for 2 h at 37 • C, and then supplemented with 300 µL PM and 500 µL differentiation medium, which contained DMEM (4.5 g/mL glucose, Life Technologies, UK), 10 ng/mL biotin (Sigma, UK), 0.5% hormone mixture (1 mg/mL apotransferrin, 20 mM putrescine, 4 µM progesterone, 6 µM selenium (formulation based on N2 mix of [35] 50 nM hydrocortisone, and 0.5 mg/mL insulin known as DM+, or DM-if lacking insulin (all reagents from Sigma, UK). Each dish was fed three times a week with DM+ for 12 DIV then DM-for the following 16 DIV. To assess the effect of glycomolecules on developmental myelination, cultures were treated at 13 DIV and 20 DIV (1 nM), following which, the cultures were fixed and stained at 28 DIV.
Myelinating Injured Cultures (MC-Inj)
MC-Inj cultures were generated based on previously published methods [7, 8] . At 24 DIV, when myelination had begun myelinating, cultures were cut using a 11 mm single edge razor blade (WPI, Aston, UK) pressed gently across the center of the coverslip. The cut created a focal cell free area (650 µm) with a decrease in adjacent neurite density and myelination levels, along with a very low number of neurites crossing the cut area site, referred to as the lesion. Using these cultures' myelination, neurite density and outgrowth could be assessed using immunocytochemistry. The cultures were treated with the panel of glycomolecules at various concentrations at 25 DIV and allowed to recover for a further 5 DIV. Cultures were then fixed and stained as described in Section 2.6.
Demyelinated Cultures (MC-Demy)
MC-Demy cultures were generated based on our previously published methods [9, 10] . At 24 DIV, myelinating cultures were demyelinated by overnight incubation with the Z2 antibody (100 ng/mL Hybridoma, a kind gift from Christopher Linington, University of Glasgow), which recognises myelin oligodendrocyte glycoprotein (MOG) and a rabbit complement (100 µg/mL, Millipore, Watford, UK) at 37 • C. The demyelinated cultures were then treated with the panel of glycomolecules at various concentrations, following which, cultures were fixed and stained at 30 DIV. Additionally, a conditioned medium was collected at 28 DIV for CytoTox 96 ® Non-Radioactive Cytotoxicity Assay (Promega G1780, Southampton, UK) to assess the viability of cultures under treatment following manufacturers guidelines.
Immunocytochemistry
Myelinating cultures were fixed with 4% paraformaldehyde (4% PFA, Sigma, UK) for 20 min at room temperature (RT) and permeabilised with 0.2% Triton X-100 (Sigma, UK) at RT for 15 min, once the washed cultures had been blocked with phosphate-buffered saline (PBS) with 0.2% porcine gelatin (blocking buffer, Sigma, UK) for 1 h at RT. The primary antibodies were diluted in a blocking buffer, and the cells were incubated for 1 h at RT. Mature myelin (proteolipid protein, PLP) was visualised using the AA3 antibody (1:100, anti-rat; hybridoma supernatant [36] ), and a neurofilament was detected using SMI31 (mouse IgG1, 1:1500, BioLegend, London, UK). After washing, the cultures were incubated with the appropriate secondary antibodies for 45 min at RT, and mounted in a Vectashield (Vector Laboratories, Peterborough, UK).
Microscopy and Image Analysis
For all myelinating cultures, the coverslips were imaged using Olympus BX51 (Olympus, Essex, UK) or LAS AF Leica DM4000 B fluorescence microscopes (Leica Microsystems, Milton Keynes, UK), with the experimenter blinded to the conditions [6] . For quantitative analysis of MC-Inj, the region adjacent to the lesion edge running 0-670 µm across the length of the coverslip was imaged at 20× magnification to allow quantification of neurite density and myelination at the end of the experiment. For quantification of neurite outgrowth, the entire length of the injury site was imaged, with the exception of areas that were folded due to the mechanical effect of cutting, which were not imaged [7] . For MC-Dev and MC-Demy quantification of re/myelination and neurite density, images were taken at 10× magnification (as seen from example images in Figure 1 ). For each coverslip, 10 images were taken randomly, covering the entire coverslip. In each biological repeat, coverslips were stained in triplicate; thus, 30 images were taken per condition (at least n = 3 biological repeats). The analysis of treated cultures was carried out by a comparison to non-treated control cultures run in parallel. (non-treated injured cultures and non-treated demyelinated cultures for MC-Inj and Demy, respectively).
Re/myelination Quantification
For all myelinating cultures, the coverslips were stained using antibodies SMI31 and AA3 for neurites and myelin, respectively. Quantification of re/myelination was carried out using CellProfiler Image Analysis software (Broad Institute) and is available to download at https://github.com/muecs/ cp [37, 38] . CellProfiler uses pattern recognition software to distinguish between linear myelinated internodes and oligodendrocyte cell bodies. In this manner, we track the co-expression of myelin sheaths (PLP) and axons (SMI31), which ignores oligodendrocytes that do not contact axons, and therefore allows us to calculate the percentage of myelinated fibers.
Neurite Outgrowth
Neurite outgrowth was defined as an SMI31 positive projection, which enters and crosses the lesion site. The number of neurites that crossed the lesion site was counted for each image. Any uninjured area around the lesion was excluded from analysis. Regions of neuronal bundles typically extended from one dense region and were, therefore, quantified as one projection, if individual neurites could not be detected. The number of neurites per image was averaged across the lesion and termed neurite outgrowth per field of view.
Statistical Analysis
Data are presented as the mean + SEM and were analysed using ANOVA with a Dunnett post-test for multiple comparisons using Prism software version 6.0 (GraphPad Software, San Diego, CA, USA). Differences were considered significant at p < 0.05. Each experimental n was the average of 3 technical replicates.
Results
Heparosans K5 NS and (Epi) K5 OS (H) Promote CNS Repair in MC-Inj
Tables detailing the panel of heparosans used in this investigation are shown in Figure 2a . MC-Inj cultures were treated with a titration of each heparosan (1, 10, and 100 ng/mL) followed by an assessment of myelination and neurite outgrowth (summarised in Figure 2a) . K5 NS at 1 ng/mL, 10 ng/mL, and 100 ng/mL was the only heparosan found to significantly promote myelination (~3 fold) compared to the non-treated control cultures (p = 0.0015, p = 0.015 and p = 0.0003, respectively; Figure 2b ,c). However, its epimerised form did not have a similar pro-myelinating effect, suggesting that the conformation of the uronic acid residue is important for function. Interestingly, neither forms of this heparosans had any effect on neurite outgrowth. Conversely, O-sulphated heparosan Epi K5 OS (H) promoted neurite outgrowth compared to the non-treated control cultures (Figure 2d ,e). Epi K5 OS (H) treatments at 1 ng/mL, 10 ng/mL, and 100 ng/mL resulted in a significantly increased neurite outgrowth of 51%, 43%, and 67%, respectively (p = 0.0048, p = 0.030 and p = 0.0001, respectively). These data imply that epimerisation is also a vital heparosan modification for the observed effect on neurite outgrowth.
Heparosans Do Not Affect the Development of Myelination in MC-Dev or Remyelination in MC-Demy
The same panel of heparosans (detailed in Figure 2a ) was used to treat MC-Dev and were found to have no effect on developmental myelination or on neurite density, similar to results previously published by us using sulphated polysaccharides [10] (Figure 3a,b) . This suggests that the beneficial effect on myelination following K5 NS treatment in the MC-Inj screen is unlikely to be a direct effect on the compounds ability to promote oligodendrocyte precursor cell (OPC) differentiation and/or the process of oligodendrocyte ensheathment of axons. To determine whether pro-myelinating effects could be observed in a different injury model, we tested the panel of heparosans using MC-Demy (Figure 3c,d ). Cultures were treated with each compound at 1 nM to enable a direct comparison between compounds. However, at this concentration, there were no significant improvements in remyelination observed for any of the panel, with only a small trend towards an increase after Epi K5 NS and Epi K5 NOS (H) treatment (Figure 3c,d) . A dose response for Epi K5 NS was carried out and demonstrated no significant effect on remyelination [39] . could be observed in a different injury model, we tested the panel of heparosans using MC-Demy (Figure 3c,d ). Cultures were treated with each compound at 1 nM to enable a direct comparison between compounds. However, at this concentration, there were no significant improvements in remyelination observed for any of the panel, with only a small trend towards an increase after Epi K5 NS and Epi K5 NOS (H) treatment (Figure 3c,d) . A dose response for Epi K5 NS was carried out and demonstrated no significant effect on remyelination [39] . 
Fucoidans or Ulvans Did Not Affect the Level of Remyelination in MC-Demy
Details of the panel of fucoidans and ulvans screened in MC-Demy are shown in Figure 4a ,b. Fucoidans (Figure 4c,d ) and ulvans (Figure 4e ,f) were used to treat MC-Demy at 1 nM and 1 µM concentrations. None of the fucoidans or ulvans at either concentration had any effect on remyelination or neurite density. A toxicity screen was also carried out for each fucoidan and ulvan via collection of the growth medium from the cultures after treatment. This conditioned medium was assessed for cellular toxicity using a cytotox non-radioactive assay. It was found that treatments at the higher concentration of 1 µM for fucoidans 1, 4, and 5 (Fuc1, Fuc4, Fuc5) were toxic to cultures as indicated in the 28 DIV toxicity screen (Figure 4g ). Conversely, none of the ulvans had any toxic effects even at 1 µM. 
CX-01 Promotes Remyelination in MC-Demy
We also assessed the effect of CX-01 in MC-Demy using a titration ranging from 1 ng/mL to 1000 ng/mL. Treatment with CX-01 resulted in a significant increase in remyelination compared to the non-treated demyelinated control cultures (Demy5) at 50 ng/mL and 250 ng/mL (Figure 5a ,b, p = 0.02). CX-01 had no effect on neurite density (Figure 5c ). We also assessed if CX-01 was cytotoxic, by testing the growth medium after drug treatment. CX-01 was found not to be cytotoxic to the cultures supporting its potential use in treating neural cells (Figure 5d ). (c) Quantification of neurite density showed no effect. (d) Conditioned media from the cultures were collected at 28 DIV, 2 days prior to immunolabelling, and used to assess cytotoxicity based on LDH levels. Quantification of cytotoxicity showed no change after treatment implying no adverse toxic effects on the cultures. Scale bars represent 100 µm in all images, error bars + SEM (n = 6; technical replicates = 3).
Discussion
In this study, we have used several modifications of myelinating cultures to screen a range of glycomolecules that mimic the HS found around the ECM and cell surface. HS are known to modulate the biological activity of a diverse range of molecules including chemokines, growth factors, morphogens, and adhesion molecules leading to a regulatory role in many physiological and pathological conditions [17] . They have also been used as pharmacological agents to treat a range of diseases [40, 41] . The application of therapeutics for cancer treatment has been reported for non-coagulant heparin (SST001) and a phosphomannopentaose sulphate (PI-88) that targets heparanase [40, 41] . PI-88 is in clinical trial for the treatment of liver cancer, non-small cell lung cancer, melanoma, and prostate cancer (ClinicalTrials.gov). Similarly, CX-01 is currently in clinical trials for myeloid leukaemia and cervical cancer [42] . Thus, it is clear that these HS mimetics have the potential to treat human disease and have been shown to produce very few side effects. However, there is no evidence from clinical trials that these molecules can be used to aid repair following CNS disease/injury.
Previously, we demonstrated using a panel of mHeps that the level of sulphation effected their potential to promote re/myelination and neurite outgrowth as well as decreasing characteristics of astrogliosis with only low sulphated mHeps promoting repair [11] [12] [13] . Moreover, their mechanism-of-action appeared to function via sequestering molecules that inhibited the repair process [10] . This was substantiated by other studies, which demonstrated that heparin promotes PNS myelination in DRG via the specific inhibition of the soluble immunoglobulin (Ig)-containing isoforms of neuregulin 1 (i.e., NRG1 types I and II), which negatively regulate myelination [43] .
These data were encouraging and lead us to consider whether other similar sulphated glycomolecules would be useful for CNS repair. However, to test these reagents in animal models is both time consuming and requires a large number of animals. For this reason, we screened the panel of glycomolecules using our three modified myelinating cultures. It was found that only CX-01 and K5 NS demonstrated comparable pro-myelinating results, as seen previously for the low sulphated mHeps [10] . This suggests that N-sulphation is an important facet for promoting CNS myelination following injury. This is supported by a recent structure relationship activity study, which highlighted the importance of N-sulphation in facilitating specific protein interactions [16] . Conversely, the number of neurites crossing the lesion was only increased following treatment with highly sulphated epimerized Epi K5 OS (H), implying that O-sulphation might be a desirable feature for eliciting beneficial neurite outgrowth effects. The presence of O-sulphate moieties was deemed essential to the activity of K5 derivatives as FGF signalling inhibitors [44] . Furthermore, modulation of 6-O-sulphation has been shown to be imperative to Wnt signaling, which is known to regulate numerous aspects of neural precursor development [45] [46] [47] [48] . Our data suggests that the epimerization state of the uronic acid may be a key structural feature for effecting myelination and neurite outgrowth. Thus, the epimerisation of glucuronic acid to its C5 epimer could be important for protein binding. The iduronic acid residue has additional conformational flexibility due to its ability to reside in the skew boat conformation; the subsequent kinking of the backbone could improve protein binding [49, 50] . Interestingly, neither ulvans nor fucoidans had any effect on remyelination; these glycomolecules are composed of fucose/galactose and rhamnose/xylose/uronic acid respectively. This suggests that the glucosamine-uronic acid repeating sugar backbone present in K5 NS and CX-01 is imperative to the HS function in regulating CNS cell biology. The molecular weight and the concomitant degree of polymerisation is also a key feature for GAG activity-for example, the depolymerisation of fucosylated glycosaminoglycan reduced anticoagulant activity in vitro [51] . Hence, we assessed both the high and low molecular weight derivatives of fucoidans and ulvans using our cultures, but this had no effect on the lack of activity following treatment.
Using these modified myelinating cultures allowed us to pre-screen panels of glycomolecules, and to assess parameters, including myelination, remyelination, neurite density, and neurite outgrowth, before validation in vivo. Moreover, molecular techniques, such as PCR and Western Blotting, can be used to quantify data and examine the mechanism of action of treatment [7, 8, 10] or direct visualisation using time lapse [2] . Since these cultures contain many neural cells types, we can also make indirect observations by comparing drug treatment on the monocultures of OPCs, astrocytes, and microglia with the myelinating cultures. This, in turn, allows the investigation of cross-talk between the neural/immune cells present in the complex cultures, as previously discussed [52] . These cultures can, therefore, mimic aspects of the cellular interactions that occur in vivo.
Conclusions
In summary, the present study has demonstrated the efficacy of complex myelinating cultures modified to examine features of CNS repair to gain important information on a large panel of glycomolecules. Thus, we propose using such cultures as a useful, moderate screen to be used before testing potential therapeutic effects in animal models.
